Physician profile
Christopher Micallef
NPI 1154557502
$15,742.58
in general payments reported to CMS, 2019-2025
20 companies · $1,222 in 2025
The $1,222 reported for 2025 was more than what a typical Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $604 · 2021: $2,993 · 2022: $2,723 · 2023: $4,021 · 2024: $3,380 · 2025: $1,222.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,104 · Travel and Lodging: $3,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,103.94 |
| Travel and Lodging | $3,518.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,090.91 | 2023-2025 | |
| Allergan, INC. | $2,969.57 | 2021-2022 | |
| Tela Bio, INC. | $1,791.52 | 2022-2024 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Sientra, INC. | $899.72 | 2022 | |
| Zimmer Biomet Holdings, INC. | $788.19 | 2019 | |
| Mentor Worldwide LLC | $686.00 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer |
| Next Science LLC | $481.89 | 2023 | Blastx, Xperience, Surgx |
| Bard Peripheral Vascular, INC. | $332.56 | 2021 | |
| Stryker Corporation | $301.53 | 2020 | |
| Solta Medical, A Division of Bausch Health US, LLC | $234.01 | 2020-2024 | Clear+Brilliant |
| Revance Therapeutics, INC. | $204.53 | 2025 | Daxxify |
| Davol INC. | $198.36 | 2022 | |
| Organogenesis INC. | $181.87 | 2023-2024 | Puraply Antimicrobial |
| Becton, Dickinson and Company | $159.65 | 2022 | |
| Kerecis Limited | $141.08 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acell, INC. | $124.24 | 2020 | |
| Merz North America, INC. | $84.34 | 2024 | |
| Galderma Laboratories, L.P. | $43.09 | 2025 | |
| Pacira Pharmaceuticals Incorporated | $17.52 | 2024 | Exparel |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Micallef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.